InterCure raises NIS 67.4 million in IPO

The firm's device, which guides breathing to lower blood pressure, has FDA approval.

Medical device start-up InterCure Ltd. has raised in NIS 67.4 million in its IPO at a company value of NIS 215 million ($50 million) before money. The date for the flotation was determined by the institutional tender held a few weeks ago, in which orders received accounted for 80% of the total share capital for the flotation.

Since the IPO was guaranteed by underwriter allotments, InterCure was not under any sort of pressure, although ultimately, the company's underwriters did not need to exercise their obligations and the flotation was held at the lower end of the price range. Poalim I.B.I.- Underwriting and Issuing Ltd. was the lead underwriter for the IPO with Rosario Capital Ltd. and Africa-Israel Issuing Ltd. as secondary underwriters. Around NIS 10 million of the IPO proceeds will be earmarked for the repayment of credit the company received from Mizrahi Tefahot Bank (TASE:MZTF).

InterCure's principal shareholders following the IPO are co-founder and chief science officer Dr. Benjamin Gavish who invented the company's lead device (13.2%); his son, CEO Erez Gavish (8.6%); Yaacov Shachar (14.4%); Medica Venture Partners (13.5%), and Palladin Capital (13.4%). Company chairman Daniel Plotkin is also a key party-at-interest in the company.

InterCure's flagship device, "RESPeRATE" has received US Food and Drug Administration (FDA) approval for use as a non-invasive device for regulating blood pressure. The device uses a personalized musical melody composed of two distinct inhale and exhale guiding tones, designed to help users regulate their breathing patterns in order to lower their blood pressure. One 15 minute session a day, several times a week, has been found to significantly reduce blood pressure, and it represents an alternative to biofeedback devices and meditative and yoga methods, as well as blood pressure medication.

The company has been marketing RESPeRATE since 2002, and most of its sales are in the US. It recorded NIS 9.9 million sales in the first quarter of 2007, but still posted a NIS 3.6 million loss, primarily due to marketing expenses.

Published by Globes [online], Israel business news - - on July 31, 2007

© Copyright of Globes Publisher Itonut (1983) Ltd. 2007

View comments in rows
Update by email about comments talkback
Your name
Please insert your name
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Biolight jumps on strong Zacks recommendation

Zacks cites the company for its technology, products, and meeting its targets.

VBL Therapeutics raises $40m in revived Nasdaq IPO

After the fiasco of the failed IPO in August, the drug development company scaled down the offering.

Assuta Hospital Gov't plans taxing private hospitals

The tax is one of the recommendations of the Economic Arrangments bill.

Erez Vigodman Teva boosted by European drug recommendations

Teva's share jumped 4% in Tel Aviv, after climbing 4.9% on Wall Street.

Partner/Orange Partner launches smartphone medical services

The new services includes prescriptions, hospital referrals, and confirmation of illness.

Reuven Krupik Clal Biotech unit PolyHeal nears licensing deal

PolyHeal has signed an MOU with a European drug company for an exclusive global license.

Nasdaq Galmed jumps on FDA hepatitis drug approval

The FDA awarded Fast Track Designation to aramchol for the treatment of Non-Alcoholic Steato-Hepatitis.

artificial sweeteners Weizmann Inst: Sweeteners cause diabetes, obesity

A study found that artificial sweeteners adversely affect intestinal bacteria.

BioCancell share jumps on positive cancer trial results

The clinical trials demonstrated safety and effectiveness of the treatment on high-risk bladder cancer patients.

Trendlines Group set for Toronto IPO

The technological incubators company is raising C$9 at a company value of C$80 million, after money.

Reuven Krupik Clal Biotech sues Hyperion for $200m

Clal Biotechnology alleges Hyperion made "rash and ill-considered" decisions in the Andromeda affair.

pharmaceuticals Clal Biotech: No evidence of misconduct by us

Clal Biotech says documents it was shown by Hyperion do not indicate it committed any misconduct regarding Andromeda.

Soroka Hospital  picture: Eyal Yitzhar Visiting Israel’s wounded at Soroka

Soroka Medical Center in Beersheva, the Israeli hospital closest to Gaza, bears the medical brunt of Operation Protective Edge.

Twitter Facebook Linkedin RSS Newsletters גלובס